In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...

SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two ...

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington ...

Drs. Kalyan M. Shekhda1 (Royal Free Hospital, London, UK), Shaunak Navalkissoor Royal Free Hospital, London, UK), and Ashley B. Grossman (University of Oxford and Queen Mary University of London, ...

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for ...

The radioactive drug industry is booming. The radiopharmaceuticals market is expected to grow 10% a year to reach more than ...

A schematic of the study. The simple targeted alpha-particle therapy (TAT) compound was made by joining the radionuclide astatine-211 to an azide. The TAT compound was injected into a mice that had ...

MTX and VBL treatment for patients with desmoid tumors resistant to meloxicam treatment: Relationship between efficacy and CTNNB1 mutation status. This is an ASCO Meeting Abstract from the 2014 ASCO ...

Metastatic melanoma, also known as stage IV melanoma, is a type of skin cancer that spreads to other parts of the body. It is one of the most aggressive forms of skin cancer, with current ...

[212 Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumors Administration of fractionated doses of [212 Pb]VMT-α-NET shows 100% survival in a robust model of metastatic ...